About Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a group of diseases characterized by
ineffective hematopoiesis.1 For unknown reasons, the bone marrow
begins producing dysplastic myeloid stem cells. As the cells progress toward
differentiation, they stall in the maturation process.1 These cells
have chromosomal abnormalities, typically an addition or deletion, which they
pass on to their progeny.1
The cells also produce toxins that cause extensive apoptosis of healthy cells,
helping the dysplastic cell lines achieve an advantage over healthy cells in
subsequent generations.1, 2 The result is very active hematopoiesis
that produces many immature myeloblasts and ineffective blood cells.1
Since the blasts do not mature, the population of healthy blood cells declines,
as do the functions associated with the cells.1 The consequences of
these declines can be minimal in early phases of the disease or in its mildest
forms.2 Late effects of severe disease are significant
and often terminal and can include anemia, leukemia, thrombocytopenia, or a
combination of these cytopenias.1
Diagnosing MDS
involves first ruling out other causes of symptoms, such as vitamin deficiencies
and infections.1 Bone marrow biopsies
and analyses also are required.1 The International
Prognosis Scoring System uses the variables within the World Health Organization
schema to predict patient outcomes on a 0 -
2.5 point scale. In general,
the more cytopenias, blasts and cytogenetic abnormalities the patient has,
the worse the prognosis.2
The prevalence of MDS is narrowly focused; it primarily occurs in
people age 60 or older, and especially in Caucasian men.2 The etiology of
MDS is not well known. There are no proven causes, and while it typically appears
de novo, it can occur secondary to radiation exposure or myelotoxic chemotherapy.1, 2
In this section you will find more information on the following MDS topics:
This site also provides comprehensive information on managing and treating MDS,
including current treatment
options and the latest developments in
MDS treatment.
References
- Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999; 340:1649-60
- Aplastic Anemia & MDS International Foundation, Inc. Myelodysplastic
Syndromes: Basic Explanations. Aplastic Anemia & MDS International
Foundation, Inc. Annapolis, MD; 2005:1-19.